ArticleFrontiers in molecular neuroscience2026
3-hydroxy-3-methylbutyrate (3H3MB) suppresses glioma growth and extends survival in mice.
Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive primary malignancy of the central nervous system, characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. A major contributor to its dismal clinical outcome is the highly invasive nature of glioblastoma cells, which infiltrate surrounding healthy brain parenchyma, precluding complete surgical resection and promoting therapeutic resistance. Emerging evidence suggests that the gut microbiota influences glioblastoma progression via modulation of neurotransmitter signaling and immune responses, and through alteration of microbial composition and metabolite production that impact tumor development. Building on our prior work demonstrating the relevance of the gut-brain axis in both physiological and glioma contexts, we identified a significant reduction in fecal levels of 3-hydroxy-3-methylbutyrate (3H3MB), a gut-associated leucine-derived metabolite that is chemically and metabolically distinct from the short-chain fatty acid butyrate, in glioma-bearing mice relative to their pre-tumor state. Given that 3H3MB administration has been reported to attenuate growth and proliferation in carcinoma models, we investigated its potential anti-tumor effects in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.